论文部分内容阅读
冠脉内溶栓疗法是急性心肌梗塞(AMI)新疗法中的一种。然而,冠脉内溶栓疗法中尿激酶的最理想剂量尚未确定.本文为确立尿激酶冠脉溶栓疗法的适宜剂量进行观察研究.方法:AMI 患者25例,男20,女5例,年龄37～78岁(平均59.5±11.0岁).冠脉再通组15例,男11,女4.平均年龄57.2±10.1岁;未通组10例,男9,女l,平均年龄62.6±11.5岁.用尿激酶240000IU 溶于20ml 溶液中在10分钟内注入 AMI 患者的冠脉内.可重复使用,直到冠脉再通,或最大量达960000IU,再通组有1例的尿激酶用量多达1200000IU,不通组1例的总量达1440000IU、再
Intra-coronary thrombolysis is one of the new therapies for acute myocardial infarction (AMI). However, the optimal dose of urokinase in coronary thrombolytic therapy has not been determined.Methods: 25 cases of AMI, 20 males and 5 females, aged 37 to 78 years old (mean 59.5 ± 11.0 years), 15 cases of coronary recanalization group, male 11 and female 4. The average age was 57.2 ± 10.1 years old, 10 cases failed, 9 male and female l, with an average age of 62.6 ± 11.5 Year.Urokinase 240000IU dissolved in 20ml solution within 10 minutes into AMI patients with coronary artery.Reusable until the coronary recanalization, or the maximum amount of 960000IU, recanalization group, 1 case of urokinase dosage Up to 1200000IU, the total number of unreasonable group reached 1440000IU, and then